retatrutide mechanism triple agonist glp-1 gip glucagon Retatrutide—A Game Changer in Obesity Pharmacotherapy The power of three: Retatrutide's
Description
Some studies have used patient self-reports to assess hypoglycemia prevalence
Suspected side effects from any medicine can also be reported directly via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk
Published studies suggest retatrutide produced larger mean body-weight reductions at top reported doses than tirzepatide in cohorts with obesity, although direct head-to-head trials have not been published at time of writing
The Mechanism: Why Sugar Triggers Nausea on GLP-1 Medications GLP-1 agonists slow gastric emptying and increase satiety signals to the brain
This is where Retatrutide breaks new ground
